Design of a PKC delta-specific small peptide as a theragnostic agent for glioblastoma

Abstract

Glioblastoma is an aggressive malignant brain tumor that starts in the brain or spine and frequently recurs after anticancer treatment. The development of an accurate diagnostic system combined with effective cancer therapy is essential to improve prognosis of glioma patients. Peptides, produced from phage display, are attractive biomolecules for glioma treatment because of their biostability, nontoxicity, and small size. In this study, we employed phage display methodology to screen for peptides that specifically recognize the target PKC delta as a novel biomarker for glioma. The phage library screening yielded four different peptides displayed on phages with a 20- to 200-pM K-d value for the recombinant PKC delta catalytic domain. Among these four phage peptides, we selected one to synthesize and tagged it with fluorescein isothiocyanate (FITC) based on the sequence of the PKC delta-binding phage clone. The synthetic peptide showed a relative binding affinity for antibody and localization in the U373 glioma cell. The kinase activity of PKC delta was inhibited by FITC-labeled peptide with an IC50 of 1.4 mu M in vitro. Consequently, the peptide found in this study might be a promising therapeutic agent against malignant brain tumor. (c) 2016 Elsevier Inc. All rights reserved.